Literature DB >> 34012622

Short-term outcomes of laparoscopic versus open total gastrectomy after neoadjuvant chemotherapy: a cohort study using the propensity score matching method.

Yinkui Wang1, Xiaokang Lei1, Zining Liu1, Fei Shan1, Xiangji Ying1, Ziyu Li1, Jiafu Ji1.   

Abstract

BACKGROUND: Until now, little is known about the benefit of laparoscopic total gastrectomy (LTG) after neoadjuvant chemotherapy (NACT). This study was designed to compare the safety and efficacy of the LTG versus the open total gastrectomy (OTG) approach after NACT treatment in patients with advanced gastric cancer (AGC).
METHODS: This study involved a cohort of 145 patients with AGC who underwent total gastrectomy after NACT at our centre between April 2013 and August 2018 including 24 cases of LTG and 121 OTG. The baseline characteristics were matched based on 1:2 balanced propensity score-matching method.
RESULTS: Sixty-nine marched cases were finally analysed (23 LTG vs. 46 OTG). All patients underwent R0 resection. Compared to the OTG group, the LTG group had a longer surgery duration (P<0.001), but a shorter incision length (P<0.001) and less intravenous patient-controlled analgesia (IV-PCA) time after surgery (P=0.027). No statistical differences were observed in terms of blood loss, retrieved lymph nodes (LNs), resection margin, length of stay, postoperative pain intensity, and complications (P>0.05).
CONCLUSIONS: LTG had comparable safety and histological findings to OTG after NACT in the perioperative period; however, LTG is less invasive and patients can benefit from less IV-PCA use. Further research is needed to investigate long-term effects. KEYWORDS: Gastric cancer (GC); neoadjuvant chemotherapy (NACT); safety; laparoscopic technique. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Year:  2021        PMID: 34012622      PMCID: PMC8107629          DOI: 10.21037/jgo-20-374

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  56 in total

Review 1.  Lymph nodes and gastric cancer.

Authors:  Natalie G Coburn
Journal:  J Surg Oncol       Date:  2009-03-15       Impact factor: 3.454

Review 2.  Laparoscopic vs open total gastrectomy for gastric cancer: a meta-analysis.

Authors:  Jun-Jie Xiong; Quentin M Nunes; Wei Huang; Chun-Lu Tan; Neng-Wen Ke; Si-Ming Xie; Xun Ran; Hao Zhang; Yong-Hua Chen; Xu-Bao Liu
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

3.  Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer.

Authors:  M Degiuli; M Sasako; A Ponti
Journal:  Br J Surg       Date:  2010-05       Impact factor: 6.939

Review 4.  Survival benefit of neoadjuvant chemotherapy for resectable cancer of the gastric and gastroesophageal junction: a meta-analysis.

Authors:  Lei Jiang; Ke-hu Yang; Quan-lin Guan; Yan Chen; Peng Zhao; Jin-hui Tian
Journal:  J Clin Gastroenterol       Date:  2015 May-Jun       Impact factor: 3.062

5.  The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging.

Authors:  Haejin In; Ethan Ravetch; Marisa Langdon-Embry; Bryan Palis; Jaffer A Ajani; Wayne L Hofstetter; David P Kelsen; Takeshi Sano
Journal:  Gastric Cancer       Date:  2017-09-25       Impact factor: 7.370

6.  The short-term outcome in esophagogastric junctional adenocarcinoma patients receiving total gastrectomy: laparoscopic versus open gastrectomy--a retrospective cohort study.

Authors:  Liu Hong; Yu Han; Yan Jin; Hongwei Zhang; Qingchuan Zhao
Journal:  Int J Surg       Date:  2013-06-21       Impact factor: 6.071

7.  Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database.

Authors:  David D Smith; Rebecca R Schwarz; Roderich E Schwarz
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

8.  Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report--a phase III multicenter, prospective, randomized Trial (KLASS Trial).

Authors:  Hyung-Ho Kim; Woo Jin Hyung; Gyu Seok Cho; Min Chan Kim; Sang-Uk Han; Wook Kim; Seung-Wan Ryu; Hyuk-Joon Lee; Kyo Young Song
Journal:  Ann Surg       Date:  2010-03       Impact factor: 12.969

Review 9.  Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach.

Authors:  Jun Haeng Lee; Jae G Kim; Hye-Kyung Jung; Jung Hoon Kim; Woo Kyoung Jeong; Tae Joo Jeon; Joon Mee Kim; Young Il Kim; Keun Won Ryu; Seong-Ho Kong; Hyoung-Il Kim; Hwoon-Yong Jung; Yong Sik Kim; Dae Young Zang; Jae Yong Cho; Joon Oh Park; Do Hoon Lim; Eun Sun Jung; Hyeong Sik Ahn; Hyun Jung Kim
Journal:  J Gastric Cancer       Date:  2014-06-30       Impact factor: 3.720

10.  The influence of neoadjuvant chemotherapy on gastric cancer patients' postoperative infectious complications: What is the negative role played by the intestinal barrier dysfunction?

Authors:  Zhiliang Wei; Bin Tan; Shougen Cao; Shanglong Liu; Xiaojie Tan; Zengwu Yao; Na Yin; Jiante Li; Dongfeng Zhang; Yanbing Zhou
Journal:  Oncotarget       Date:  2017-06-27
View more
  2 in total

1.  Short and long-term outcomes between laparoscopic and open total gastrectomy for advanced gastric cancer after neoadjuvant chemotherapy.

Authors:  Hao Cui; Ke-Cheng Zhang; Bo Cao; Huan Deng; Gui-Bin Liu; Li-Qiang Song; Rui-Yang Zhao; Yi Liu; Lin Chen; Bo Wei
Journal:  World J Gastrointest Surg       Date:  2022-05-27

2.  Meta-Analysis of the Effects of Three-Dimensional Visualized Medical Techniques Hepatectomy for Liver Cancer with and without the Treatment of Sorafenib.

Authors:  Lei Zeng; Yuming Zhu; Peng Guo
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-13       Impact factor: 2.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.